# GEN1047 for Solid Tumors - First in Human (FIH) Trial

> **NCT05180474** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genmab** · enrollment: 179 (actual)

## Conditions studied

- Breast Cancer, Breast Neoplasms
- Endometrial Cancer, Endometrial Neoplasm
- Ovarian Cancer, Ovarian Neoplasms
- Squamous Non Small Cell Lung Cancer (NSCLC-SCC)

## Interventions

- **BIOLOGICAL:** GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.

## Key facts

- **NCT ID:** NCT05180474
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-13
- **Primary completion:** 2026-03-25
- **Final completion:** 2026-03-25
- **Target enrollment:** 179 (ACTUAL)
- **Why stopped:** The Sponsor has made a strategic decision to stop the development of GEN1047.
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05180474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05180474, "GEN1047 for Solid Tumors - First in Human (FIH) Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05180474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*